Metropolis Healthcare Limited Reports ₹4,169.34 Crore Q2 Revenue

Metropolis Healthcare Limited reported revenue from operations of ₹4,169.34 crore and net profit of ₹687.51 crore for the quarter ended September 30, 2026, and declared an interim dividend of ₹1 per share. The board-approved unaudited results also showed six-month revenue of ₹7,892.18 crore, making the update relevant for shareholders tracking earnings and dividend eligibility.

What did Metropolis Healthcare Limited report for the September quarter?

Metropolis Healthcare Limited reported unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2026. Revenue from operations for the quarter was ₹4,169.34 crore, compared with ₹3,554.57 crore in the comparable figure cited in the results information. Net profit was ₹687.51 crore, against ₹506.54 crore in the prior-quarter comparison provided.

For the six-month period, revenue from operations stood at ₹7,892.18 crore, compared with ₹6,787.27 crore in the corresponding comparison. The company’s board considered and approved the results at its meeting scheduled for November 3, 2026. The board-meeting intimation issued on October 28 had stated that the directors would consider both the September-quarter results and an interim dividend for FY2027.

The supplied results information refers to the quarterly revenue figures as Q3 2026 and Q3 2025 in one instance, while the board communication and reporting period identify the results as the quarter ended September 30, 2026, or Q2 FY2027. The financial figures and stated reporting date are therefore presented as disclosed, without treating the quarter label in that reference as a separate reporting period.

What interim dividend has Metropolis Healthcare Limited declared?

Metropolis Healthcare Limited declared an interim dividend of ₹1 per equity share for FY2027 alongside the unaudited results. The results information states that the record date is November 9, 2026, and that payment will be made within 30 days of the declaration.

A shareholder’s entitlement depends on holding the shares in accordance with the record-date process set by the company and the depository system. The ₹1 per-share declaration is the specific corporate action connected with the November 3 board decision, rather than a reference to earlier dividend actions.

The company’s previously listed corporate actions include an interim dividend of ₹1 per share with an ex-date and record date of May 19, 2026. It also declared an interim dividend of ₹4 per share in November 2025. Those actions relate to earlier announcements and should not be confused with the record date of November 9, 2026 stated for the latest declared dividend.

How do these results compare with earlier disclosures?

Metropolis Healthcare Limited’s reported quarterly revenue of ₹4,169.34 crore was higher than the ₹3,554.57 crore comparison figure supplied with the results. Likewise, net profit of ₹687.51 crore was above the ₹506.54 crore prior-quarter comparison. The six-month revenue figure of ₹7,892.18 crore was also above the stated ₹6,787.27 crore comparison.

Earlier information on the company’s financial performance provides additional context. For Q2 FY2025-26, Metropolis Healthcare had reported consolidated revenue of ₹4,291.91 million and net profit of ₹528.90 million, alongside an interim dividend of ₹4 per share. For FY26, information supplied in the source stated that revenue rose 24% to ₹1,646 crore and profit after tax rose 31% to ₹191 crore.

Metropolis Healthcare also completed a 3:1 bonus-share action in March 2026, according to the corporate-action details provided. Its shareholders approved FY26 financial statements and a ₹5 per-share dividend at the company’s 26th annual general meeting on August 18, 2026. The source also stated that the company had set a 13% to 15% growth target for FY27.

What does the update mean for shareholders and the diagnostics sector?

For shareholders, the update combines an earnings disclosure with a cash-distribution decision. Revenue, profit and six-month revenue were all reported above their respective comparison figures, while the ₹1 per-share interim dividend provides a defined distribution subject to the November 9, 2026 record date disclosed in the results information.

The results are also relevant to investors assessing operating scale in the diagnostic-services sector. Revenue from operations is a central measure of the company’s diagnostic business activity, while reported net profit indicates the earnings retained after expenses and other applicable items. The information provided does not set out operating margins, test volumes, geographic performance, or segment-level contributions, so those measures cannot be assessed from this announcement alone.

For customers and industry participants, the filing does not announce any change to testing services, prices, laboratories, or operating locations. It is primarily a financial-results and corporate-action disclosure. The company has reported both standalone and consolidated unaudited results, although the supplied text does not provide a separate numerical reconciliation between those two bases.

Conclusion

Metropolis Healthcare Limited’s September-quarter update reported revenue from operations of ₹4,169.34 crore, net profit of ₹687.51 crore and six-month revenue of ₹7,892.18 crore. The board also declared a ₹1-per-share interim dividend, linking the financial announcement to a near-term corporate action for eligible shareholders.

The immediate item to watch is the November 9, 2026 record date and the company’s stated plan to make dividend payment within 30 days. Investors may also track future disclosures for further detail on the FY27 growth target of 13% to 15%, operating performance and the basis of quarterly comparisons.